Show Summary Details
Page of

Adjuvant Therapy for High-Risk Melanoma: Radiation Therapy 

Adjuvant Therapy for High-Risk Melanoma: Radiation Therapy
Chapter:
Adjuvant Therapy for High-Risk Melanoma: Radiation Therapy
Author(s):

Michael D. Chuong

, Mohammad K. Khan

, and Nikhil G. Rao

DOI:
10.1093/med/9780199971015.003.0007
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 October 2019

While surgical management is the mainstay of treatment for patients with invasive cutaneous melanoma, adjuvant radiation therapy (RT) to the primary site and/or the adjacent nodal regions can provide significant benefit to patients at high risk for local or regional recurrence. Due to early preclinical and clinical reports that melanoma is radioresistant, many clinicians have been hesitant to recommend RT. However, subsequent studies have shown melanoma to be responsive to RT and RT to be a critical component of the comprehensive treatment for select patients with cutaneous melanoma. The use of radiotherapy in the future for melanoma is likely to play a greater role, especially combined with newer emerging systemic agents such as CTLA4 inhibitors, PD-1 inhibitors, BRAF inhibitors, and potential radiation sensitizers such as the MEK inhibitor, trametinib.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.